{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:43:40Z","timestamp":1787755420364,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02663-x","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:47:26Z","timestamp":1750740446000},"page":"1865-1870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bonmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zilliox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Laloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-8537","authenticated-orcid":false,"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1999-0204","authenticated-orcid":false,"given":"Maria Pilar Gallego","family":"Hernanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Ochmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1127","authenticated-orcid":false,"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha","family":"Chermat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Caulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-7391","authenticated-orcid":false,"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Marolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2663_CR1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","volume":"103","author":"L Ad\u00e8s","year":"2018","unstructured":"Ad\u00e8s L, Thomas X, Bresler AG, Raffoux E, Spertini O, Vey N, et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica. 2018;103:2033\u20139.","journal-title":"Haematologica"},{"key":"2663_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295\u2013305.","journal-title":"Lancet Oncol"},{"key":"2663_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35662","volume":"131","author":"W-Y Jen","year":"2025","unstructured":"Jen W-Y, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, et al. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025;131:e35662.","journal-title":"Cancer"},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/bloodadvances.2021005642","volume":"6","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, et al. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Adv. 2022;6:376\u201385.","journal-title":"Blood Adv"},{"key":"2663_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/s41375-020-0758-4","volume":"34","author":"S Kayser","year":"2020","unstructured":"Kayser S, Rahm\u00e9 R, Mart\u00ednez-Cuadr\u00f3n D, Ghiaur G, Thomas X, Sobas M, et al. Outcome of older (\u226570 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia. 2020;34:2333\u201341.","journal-title":"Leukemia"},{"key":"2663_CR6","unstructured":"Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. S. Karger. Basel, 1995."},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","volume":"116","author":"BL Powell","year":"2010","unstructured":"Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751\u20137.","journal-title":"Blood"},{"key":"2663_CR8","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","volume":"112","author":"MA Sanz","year":"2008","unstructured":"Sanz MA, Montesinos P, Vellenga E, Ray\u00f3n C, De La Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112:3130\u20134.","journal-title":"Blood"},{"key":"2663_CR9","doi-asserted-by":"publisher","unstructured":"Muchtar E, Vidal L, Ram R, Gafter-Gvili A, Shpilberg O, Raanani P. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev 2013. https:\/\/doi.org\/10.1002\/14651858.CD009594.pub2.","DOI":"10.1002\/14651858.CD009594.pub2"},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2663_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1182\/blood.V116.21.1080.1080","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Estey EH, Cortes JE, O\u2019Brien S, Pierce SA, Brandt M, et al. Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL). Blood. 2010;116:1080.","journal-title":"Blood"},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","volume":"4","author":"JE Lancet","year":"2020","unstructured":"Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020;4:1683\u20139.","journal-title":"Blood Adv"},{"key":"2663_CR13","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.clml.2018.11.004","volume":"19","author":"WFda Silva","year":"2019","unstructured":"Silva WFda, Rosa LIda, Marquez GL, Bassolli L, Tucunduva L, Silveira DRA, et al. Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil - Early Deaths Are Still a Problem. Clin Lymphoma Myeloma Leuk. 2019;19:e116\u2013e122.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2663_CR14","first-page":"138","volume":"58","author":"OF Akcay","year":"2020","unstructured":"Akcay OF, Yeter HH, Buyukasik Y. Real-life outcomes of unselected acute promyelocytic leukemia patients: a single-center 14-year experience. Rom J Intern Med. 2020;58:138\u201345.","journal-title":"Rom J Intern Med"},{"key":"2663_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0284186X.2021.1971291","volume":"60","author":"S Rosati","year":"2021","unstructured":"Rosati S, Gurnari C, Breccia M, Carmosino I, Scalzulli E, Montefusco E, et al. Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta Oncol. 2021;60:1520\u20136.","journal-title":"Acta Oncol"},{"key":"2663_CR16","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/j.htct.2024.02.020","volume":"46","author":"HMF Fontes","year":"2024","unstructured":"Fontes HMF, de Freitas JP, Oliveira JHV, de Sousa Moraes \u00c9A, Rego EM, Melo RAM. Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience. Hematol Transfus Cell Ther. 2024;46:S122\u2013S128.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2663_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","volume":"103","author":"MA Sanz","year":"2004","unstructured":"Sanz MA, Mart\u00edn G, Gonz\u00e1lez M, Le\u00f3n A, Ray\u00f3n C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237\u201343.","journal-title":"Blood"},{"key":"2663_CR18","doi-asserted-by":"crossref","unstructured":"Voso MT, Guarnera L, Lehmann S, D\u00f6hner K, D\u00f6hner H, Platzbecker U, et al. Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project. Blood 2024; blood.2024026186.","DOI":"10.1182\/blood.2024026186"},{"key":"2663_CR19","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1080\/10428194.2019.1607327","volume":"60","author":"O Salamero","year":"2019","unstructured":"Salamero O, Mart\u00ednez-Cuadr\u00f3n D, Sobas M, Benavente C, Vives S, De la Serna J, et al. Real life outcomes of patients aged \u226575 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leuk Lymphoma. 2019;60:2720\u201332.","journal-title":"Leuk Lymphoma"},{"key":"2663_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2011.78","volume":"25","author":"S Lehmann","year":"2011","unstructured":"Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, M\u00f6llg\u00e5rd L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128\u201334.","journal-title":"Leukemia"},{"key":"2663_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, Ray\u00f3n C, Parody R, De La Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775\u201383.","journal-title":"Blood"},{"key":"2663_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111\u201321.","journal-title":"N Engl J Med"},{"key":"2663_CR23","unstructured":"Platzbecker U, Ad\u00e8s L, Montesinos P, Ammatuna E, Fenaux P, Baldus C et al. First results of the APOLLO trial: a randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia. EHA Library. 06\/13\/2024; 422206; S102."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02663-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:17:00Z","timestamp":1757197020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02663-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02663-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest. The authors alone are responsible for the manuscript\u2019s content.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the French National Consultative Committee on Information Processing in Medical Research (Comit\u00e9 Consultatif sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9, Paris, France; reference: 15.414), and the study database was registered with the French National Data Protection Commission (Commission nationale de l\u2019informatique et des libert\u00e9s, Paris, France; reference: DR-2015-534). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}